Back and forth in time: Directing age in iPSC-derived lineages

Area of Science:

• Stem cell biology
• Neuroscience
• Aging research

Background:

• Induced pluripotent stem cells (iPSCs) provide in vitro patient-specific cells for disease pathogenesis and drug screening.
• Current iPSC models face limitations in studying age-related diseases, particularly neurodegeneration.
• The fetal-like nature of iPSC progeny and cellular rejuvenation hinder the recapitulation of late-stage disease features.

Purpose of the Study:

• To highlight the challenges of using iPSC technology for studying age-related neurological disorders.
• To emphasize the discrepancy between the immature state of iPSC derivatives and the late onset of neurodegenerative diseases.
• To identify the need for controlling cellular age in stem cell research for aging brain disease investigation.

Main Methods:

• Review of current evidence on iPSC-based disease modeling.
• Analysis of the functional immaturity and rejuvenation effects in iPSC derivatives.
• Discussion of the implications for studying neurodegenerative conditions.

Main Results:

• iPSC technology is not fully suitable for modeling conditions of old age, such as neurodegeneration.
• Reprogramming induces a "rejuvenation" effect, making cells too "young" to manifest age-related disease phenotypes.
• A significant gap exists in recapitulating late-stage disease features in iPSC-derived cells.

Conclusions:

• The stem cell field must address the challenge of controlling cellular age to fully utilize iPSC potential.
• Harnessing iPSC technology requires overcoming the limitations imposed by cellular immaturity and rejuvenation.
• Advancing research and cures for aging brain diseases necessitates improved iPSC models that account for cellular age.